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Clinical prostatic cancer develops in approximately one in every
11 males in the Western world. It has become the most commonly
diagnosed cancer in men, and is presently the second leading cause
of cancer deaths. Localized prostate cancer can be cured by radical
prostatectomy, whereas patients suffering from extensive or
metastasized tumours usually receive androgen ablation therapy.
In spite of a high initial response rate of patients to this endocrine
treatment, its benefit is limited by tumour cells becoming
androgen-independent for their growth, leading to uncontrolled
proliferation. Peptide growth factors can also influence prostatic
growth (Ilio et al, 1995). Activins, which are composed of two
b-subunits (bA and/or bB) and their antagonists, the inhibins
(combinations of an a- and either of the two b-subunits) are
members of the transforming growth factor (TGF)-b superfamily
of peptide growth- and differentiation factors. They influence
proliferation in a variety of cell systems (Gonzalez-Manchon and
Vale, 1989; Hedger et al, 1989; Hashimoto et al, 1990). Activin
exerts its effect by binding to one of two activin type II receptors
(ActRIIA or ActRIIB), which are membrane-spanning serine/
threonine kinase receptors (Mathews, 1994). Combination of the
activin–ActRII complex with either one of the two activin recep-
tors type I (ActRIA or ActRIB) initiates a signalling cascade (ten
Dijke et al, 1994), which involves specific transcription factors,
the Smads (Massagué, 1996). The detection of ActRIIA and
ActRIIB receptor mRNA expression in the rat prostate (Feng et al,
1993) suggests an involvement of activin in the regulation of
prostatic growth. In addition, the human prostatic cancer cell lines
LNCaP and DU-145 express at least one type of activin type I
receptors, as demonstrated by reverse transcription polymerase
chain reaction (RT-PCR) (Batres et al, 1995; Furst et al, 1995;
Ying et al, 1995). Recently, the presence of immuno-reactive
inhibin/activin subunits was demonstrated in the rat prostate
(Risbridger et al, 1996) and in prostatic tissue of men with benign
prostatic hyperplasia (Thomas et al, 1998). Finally, activin has an
inhibitory effect on the growth of the human prostatic carcinoma
cancer cell line LNCaP (Dalkin et al, 1996; Wang et al, 1996b;
McPherson et al, 1997; Zhang et al, 1997a, 1997b), indicating
that the activin/inhibin system can play a role in the control of
prostate epithelial cell proliferation. Changes in expression of
inhibin/activin subunits, activin receptors or the activin-binding
protein follistatin may therefore influence growth of prostate
epithelial cells. On the basis of these data, we hypothesized that
transcript levels for activin b-subunits or activin receptors might
be lower in tumour material when compared to normal prostatic
tissue (in the case of clinical material) and in androgen-
independent cell lines and xenografts when compared to their
androgen-dependent counterparts.
Therefore we measured the mRNA expression levels of activin
type I and type II receptors, of inhibin a- and inhibin/activin
b-subunits and of follistatin by RNAase protection analyses in
androgen-dependent and androgen-independent human prostatic
xenografts, in various sublines of the human prostatic cell line
LNCaP, and in non-malignant and malignant prostate tissues.
MATERIALS AND METHODS
Cell lines, xenografts and primary tumours
The androgen-dependent LNCaP-FGC (FGC) and the androgen-
independent LNCaP-r (R) and LNCaP-LNO (LNO) sublines have
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been derived from the original LNCaP cell line (Horoszewicz et al,
1983). FGC and LNO (van Steenbrugge et al, 1991) were kindly
provided by Dr JS Horoszewicz, subline FGC being identical to
the LNCaP line available through the American Type Culture
Collection (ATCC). The R-subline (Hasenson et al, 1985) was a
gift from Dr M Hasenson (Karolinska Institute, Sweden). FGC and
R were routinely cultured in RPMI medium, supplemented with
10% fetal calf serum (FCS), glutamine and antibiotics. For
culturing LNO, regular FCS was replaced by 5% dextran-coated
charcoal (DCC)-treated, i.e. androgen-depleted, FCS. In order to
study effects of activin on cell proliferation, R cells were grown
for 5 days in DCC-treated medium with the indicated amounts of
activin A (Innogenetics, Ghent, Belgium). Growth was determined
with a colourimetric (MTT) assay, as described earlier (Romijn
et al, 1988).
The prostate tumour xenografts used in this study are the
androgen-dependent PC-82 (Hoehn et al, 1980), PC-295, PC-310,
PC-329 (van Weerden et al, 1996) and the androgen-independent
PC-133, PC-135 (van Steenbrugge, unpublished results), PC-324,
PC 339 and PC-374 (van Weerden et al, 1996).
Primary tumour material was obtained after radical prostatec-
tomy in 24 patients. From 20 sections of paraffin-embedded tissue
to be used for RNA isolation, sections 1, 10 and 20 were used for
histological examination. Based upon these observations, 12
samples were classified as normal (i.e. non-malignant) and 12 as
carcinoma (Gleason scores: G-6 (1), G-7 (1), G-8 (5), G-9 (2),
G-10 (3)).
RNA isolation and RNAase protection assays
Frozen tissue (–80°C) was pulverized in liquid nitrogen, followed
by RNA isolation using TRIzol reagent (Gibco-BRL,
Gaithersburg, MD, USA), according to the manufactures protocol.
For the cell lines, cells were washed once in phospate-buffered
saline (PBS) after which TRIzol reagent was added to the culture
flasks. RNA was dissolved in RNAase-free water and its concen-
tration and purity were determined by optical density measure-
ment at 260 and 280 nm.
cDNA clones for the specific human transcripts (van Schaik
et al, 1997) were digested with appropriate restriction enzymes
and  32P-labelled RNA probes were made by transcription in
the presence of 32P-UTP, using T3 or T7 RNA polymerase
(Stratagene, La Jolla, CA, USA). The cRNA probes protect
nucleotides 126–411 for the inhibin a-subunit (Mayo et al,
1986), nucleotides 702–946 for the bA-subunit (Mason et al,
1986), nucleotides 845–1073 for the bB-subunit (Mason
et al,1986) and nucleotides 508–819 for the follistatin transcript.
The latter probe therefore detects mRNAs, which can be translated
into both follistatin-288 and follistatin-315. For the activin recep-
tors, the cRNA probes protect nucleotides 1482–1692 for
ActRIA (ten Dijke et al, 1993), nucleotides 191–361 for ActRIB
(GenBank, accession number Z22536), nucleotides 132–791 for
ActRIIA (Donaldson et al, 1992) and nucleotides 429–947 for
ActRIIB (Hildén et al, 1994). For human g-actin, a probe corre-
sponding to nucleotides 1207–1337 (Erba et al, 1986) was used.
RNAase protection assays were performed as described by
Sambrook et al (1989). RNAase treatment was performed using
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Figure 1 Expression of activin receptor, inhibin subunit and follistatin
mRNAs in androgen-dependent LNCaP-FGC (open bars), and androgen-
independent LNCaP-R (hatched bars) and LNCaP-LNO cells (cross-hatched
bars). Signals are expressed in arbitrary units, relative to actin. Mean values
± s.e.m. are shown for three independent experiments. Significant
differences (P < 0.05) have been indicated with asterisks
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Figure 2 Effect of activin on the proliferation of the androgen-independent
cell line LNCaP-R. Cells were grown for 5 days in DCC-treated medium with
the indicated amounts of activin (n = 8). Growth was determined in a
colourimetic (MTT) assay, and plotted relative to cells grown in DCC, which
was set at 100%. Significant differences (P < 0.05) in proliferation from
control (DCC without activin) are marked with an asterisk114 RHN van Schaik et al
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100 U ml–1 RNAase T1 (Boehringer, Mannheim, Germany) in
combination with 10 mg ml–1 RNAase A (Boehringer).
Hybridization temperature was 42°C. Routinely, 5 mg RNA was
analysed. In each run, positive and negative controls were
included. Results were quantified using a PhosphorImager
(Molecular Dynamics/B&L Systems, Maarssen, The Netherlands)
and data are expressed relative to g-actin. Unless stated otherwise,
mean values ± s.e.m. are given and comparisons between groups
were made using the Mann–Whitney U-test. P-values < 0.05 were
interpreted as indicating a significant difference.
RESULTS
LNCaP sublines
In three independent experiments, we found that the androgen-
dependent FGC- and the androgen-independent R- and LNO-cell
lines expressed activin type I (ActRIA and ActRIB) and type II
(ActRIIA and ActRIIB) receptor mRNAs at comparable levels
(Figure 1). For ActRIIA mRNA expression, significantly higher
levels were found in the R-line when compared to the FGC- and
LNO-lines. Furthermore, a small but significant difference was
observed between the FGC- and LNO-line for the ActRIIB mRNA
levels. The FGC and LNO cell lines express inhibin/activin
bB-subunit mRNA, while in the R-line bB-subunit mRNA was
virtually absent. We found low inhibin/activin bA-subunit mRNA
levels in all three sublines, while expression of inhibin a-subunit
mRNA was at the detection limit of our assay. Follistatin mRNA
expression was not detectable.
The functionality of the activin signalling pathway in the
LNCaP sublines was investigated by growing the androgen-
independent R cells in the presence of varying amounts of activin.
The cells were significantly inhibited in their proliferation when
incubated on DCC-medium in the presence of activin (P < 0.05)
(Figure 2).
Prostatic carcinoma xenografts
In tissue specimens of well defined androgen-dependent and
androgen-independent xenograft models, we quantitatively
investigated expression of inhibin/activin subunits, activin recep-
tors and follistatin mRNAs. All xenografts studied expressed
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Figure 3 Relative expression of mRNA encoding activin receptors, inhibin
subunits and follistatin in human androgen-dependent (AD): PC-82 (t t), PC-
295 (D), PC-310 (l l), PC-329 (n n); and androgen-independent (AID)
xenografts: PC-133 (n), PC-135 (u), PC324 (•), PC-339 (t), PC-374 (s),
as measured by RNAase protection. Signals are expressed in arbitrary units,
relative to actin. Significant differences (P < 0.05) are indicated with an
asterisk
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Figure 4 Relative expression of mRNA encoding activin receptors, inhibin
subunits and follistatin in non-malignant (open bars) and malignant (hatched
bars) clinical prostatic tissue, as measured by RNAase protection. Signals
are expressed in arbitrary units, relative to actin. Significant differences
(P < 0.05) between the non-malignant and malignant clinical samples are
indicated with an asterisk. The numbers in parentheses indicate the number
of samples determined in each groupActivin in prostate cancer 115
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activin type I (ActRIA and ActRIB) and type II (ActRIIA and
ActRIIB) receptors (Figure 3). Inhibin/activin bA-subunit expres-
sion was not detectable in the androgen-dependent xenografts,
while of the androgen-independent xenografts only PC-324
showed a low level of expression. Inhibin/activin bB-subunit
mRNA, however, was abundantly expressed in the androgen-
dependent xenografts. This expression level was found to be
significantly lower (P < 0.05) in the androgen-independent
tumours. Follistatin mRNA was expressed with a large variation,
ranging from undetectable to a relatively high (16.8 relative units
(RU)) expression in the androgen-independent xenograft PC-324.
We could not detect inhibin a-subunit mRNA expression in the
xenograft samples.
Clinical prostatic carcinomas
In all clinical prostate samples investigated, expression of activin
type I (ActRIA and ActRIB) and type II (ActRIIA) receptors was
found, while ActRIIB expression was detected in four of seven
non-malignant prostatic tissues and in nine of eleven samples of
prostate carcinomas. The carcinomas expressed significantly
lower levels of ActRIB mRNA when compared to the non-malig-
nant tissues (15.3 ± 3.0 vs 26.0 ± 3.1 RU respectively; P < 0.05)
(Figure 4). Inhibin/activin bA- and bB-subunit mRNAs were
expressed at comparable levels in non-malignant and carcinoma-
tous samples. Inhibin a-subunit mRNA expression was low or not
detectable. Follistatin mRNA expression was generally found at
low expression levels, and was significantly lower in the carci-
nomas when compared to non-malignant tissue (P < 0.05).
DISCUSSION
Activin receptors
We measured mRNA expression levels of activin receptors type
IA, IB and type IIA, IIB in human prostate cancer cells, either in
culture, in xenografts or clinical tissues. In the three sublines of
LNCaP, significant differences were observed in the expression of
ActRIIA and ActRIIB mRNA. In prostatic carcinoma xenografts
we demonstrated expression of all known activin type I and activin
type II receptors. No significant differences in expression of
activin receptors were observed when androgen-dependent and
androgen-independent xenografts were compared. In tissue
obtained after radical prostatectomy, in which the neoplastic grade
of the samples was determined microscopically to range from non-
malignant to Gleason grade 10, expression of ActRIA and ActRIB
mRNA was found. Transcript levels for ActRIB were significantly
lower in the carcinomas when compared to the non-malignant
tissues. This implies a decreased sensitivity to growth inhibition
by activin: it was shown that ActRIB is responsible for inhibition
of proliferation by activin, rather than ActRIA (Cárcamo et al,
1994). No correlation was observed between Gleason grade and
ActRIB mRNA levels within this limited series. Expression of
ActRIIA mRNA was demonstrated in all samples, but ActRIIB
mRNA transcripts were undetectable in a number of them. These
results corroborate and significantly extend previous reports using
the reverse transcriptase polymerase chain reaction (RT-PCR) for
the qualitative detection of expression of activin receptors in
human prostate cancer cell lines (Batres et al, 1995; Furst et al,
1995; Dalkin et al, 1996), and are in line with the detection of
ActRIIA and IIB transcripts in the rat prostate (Feng et al, 1993)
and recently of ActRIIA mRNA in benign prostate hyperplasia
(Thomas et al, 1998). Remarkably, the relative signal for ActRIA
was lower than that for ActRIB in the LNCaP cell lines while in
most of the xenografts relatively more ActRIA was expressed than
ActRIB. In the clinical prostate samples expression of ActRIA and
of ActRIB were comparable; this may have been caused by the
presence of stromal tissue in these samples.
The combined expression of type I and type II receptors in
human prostatic epithelial cells indicates that a functional activin
receptor complex can be formed in the presence of activin, thereby
enabling activin to have an effect on these cells. We confirmed this
in androgen-independent R cells. These results are in line with
data reported on androgen-dependent LNCaP cells (Dalkin et al,
1996; Wang et al, 1996b), but differ with results obtained with the
androgen-independent cell lines PC3 and DU-145 (Ying et al,
1997). Possibly, the defect in the retinoblastoma gene product in
DU-145 (Rubin et al, 1991) and the expression of relatively large
amounts of follistatin by PC3 cells (Wang et al, 1996a) or the
presence of a mutated p53 gene in PC3 cells (Rubin et al, 1991)
are responsible for this lack of response to activin treatment.
Activin/inhibin subunits and follistatin
In addition to activin receptor expression, we quantified mRNA
levels for inhibin/activin b-subunits in prostate tumour cell lines,
in prostate tumour xenografts and in samples of non-malignant
and malignant prostatic tissues. Expression of predominantly bB-
subunit mRNA was found in the FGC cell line, but this expression
was virtually absent in the androgen-independent R-line.
Decreased production of activin might lead to a growth advantage;
the R-line is indeed still sensitive to growth inhibition by activin
(Figure 2). However, the other androgen-independent cell line in
our study (LNO) did not show this decreased bB-subunit expres-
sion, indicating that not all androgen-independent cell lines have
low levels of activin. For the FGC-subline, we found variable
results for inhibin/activin bB-subunit expression in three indepen-
dent experiments, resulting in a relative large variation, which
cannot be explained at this moment. The three independent
experiments were performed with relatively large time intervals;
therefore we hypothesize that, at least for this subline, variable
conditions of e.g. cell density or passage number, may have caused
the observed variation. Qualitative expression of bB-subunit
mRNA in LNCaP has been reported earlier, using RT-PCR (Batres
et al, 1995; Furst et al, 1995). Dalkin et al (1996) investigated the
effect of endogenous activin on proliferation of LNCaP-FGC cells
by addition of follistatin and found an increase in proliferation
after 24 h treatment confirming endogenous activin production.
Low, but detectable inhibin a-subunit mRNA levels were found in
the RNAase protection assay for the LNCaP sublines, whereas the
absence of inhibin a-subunit mRNA in LNCaP cells using RT-
PCR has been reported earlier (Batres et al, 1995). It is unclear
whether this difference is caused by subtle differences in proper-
ties of the LNCaP cell lines used, or culture conditions applied. On
the other hand, the RT-PCR assay may not have functioned opti-
mally, which is difficult to assess due to the absence of a positive
control for the inhibin a-subunit mRNA RT-PCR (Batres et al,
1995). Inhibin immunoreactivity was found to be absent in LNCaP
cells (Batres et al, 1995), suggesting that inhibin production in
FGC cells is indeed very low. In the xenografts, bA-subunit
expression was not detectable in the androgen-dependent samples
and was only detected at low levels in one out of three androgen-
independent tumours. RNAase protection will only measure116 RHN van Schaik et al
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expression in the epithelial component of the xenografts since
stromal cells express the murine genes which, with the exception of
ActRIIA mRNA, are not protected by the human cRNA probes
(RHN van Schaik, unpublished results). This suggests that the
stromal cells may be responsible for the inhibin bA-subunit mRNA
expression in the prostate. The androgen-independent xenografts
had significantly lower expression levels of inhibin/activin
bB-subunit mRNA when compared to the androgen-dependent
samples, indicating a decrease in activin production with increasing
malignancy. In the clinical samples we found a relatively high
expression of both bA- and bB-subunit transcripts. Inhibin
a-subunit mRNA levels in non-malignant and malignant prostate
tissues were low or undetectable as determined by RNAase protec-
tion. Using in situ hybridization and immunohistochemistry on
BPH- and prostate cancer samples, expression of inhibin a-subunit
mRNA was found in prostate epithelial and basal cells, which was
absent in malignant regions of tissue from men with high grade
prostate cancer (Mellor et al, 1998). We did not find a significant
difference in the expression of inhibin a-subunit transcript levels
when non-malignant (0.3 ± 0.3 RU) and tumour samples (0.4 ± 0.2
RU) were compared, although this may be due to the very low
expression levels detected in our study. We found a significantly
higher expression of follistatin mRNA in the non-malignant samples
when compared to the carcinomatous tissues. Because follistatin
mRNA expression was undetectable by RNAase protection in the
LNCaP sublines, follistatin might be expressed in stromal cells
rather than in the epithelial cells. In fact, follistatin immunoreac-
tivity was recently reported to be localized in fibroblastic stroma
(Thomas et al, 1998). Human follistatin mRNA expression was also
found in three out of nine xenografts studied, indicating that the
epithelial cells are also capable of expressing follistatin mRNA. In
addition, the human prostatic carcinoma cell line PC3 expresses
large amounts of follistatin (Wang et al, 1996a) while also follistatin
mRNA could be detected in LNCaP cells using RT-PCR (Dalkin
et al, 1996). All in all, these data indicate that prostate epithelial cells
can express follistatin, and suggest that the expression level in
LNCaP cells is relatively low.
Our results on mRNA expression indicate that autocrine growth
control by activin can occur in the prostate, and that malignant
cells may escape growth inhibition by activin by a decrease in
mRNA expression levels for the activin bB-subunit or for the
activin receptor type IB. Decreased activin signalling may lead to
increased cell proliferation and inhibition of apoptosis of prostate
epithelial cells (Zhang et al, 1997a), thereby facilitating prostate
tumour development. Future experiments need to establish to what
extent the differences found in mRNA levels can be translated to
the protein level and can lead to differences in the behaviour of the
tumours.
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